Sarcoma trials in Germany
26 of 32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Bielefeld, Greifswald, Solingen, Stuttgart
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 1Taking peopleSTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
- Where
- Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
- Age
- 18 years and over
- People
- 15 worldwide
- Run by
- Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Berlin, Bielefeld, Essen, Esslingen am Neckar, Gauting, Homburg, Offenbach Am Main, Oldenburg, Regensburg, Stuttgart, Wuerzburg
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - Phase 1Not yet taking people in GermanyGD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
- Where
- Münster
- Age
- 1 year to 25 years
- People
- 30
- Run by
- Universität Münster
See details and how to joinNCT07897968 - Phase 1Taking peopleInternational Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma
- Where
- Berlin, Essen, Göttingen, Greifswald, Mainz
- Age
- 12 months and over
- People
- 18
- Run by
- Prof. Dr. Dr. Birgit Burkhardt
See details and how to joinNCT06839703 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Berlin, Cologne, Giessen, Muenster, Tuebingen
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 3Taking peopleInternational Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bielefeld, Bonn, Bremen, Brunswick, Chemnitz, Cologne, Cottbus, Datteln, Dortmund, Dresden, Duesseldorf, Erfurt, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Gießen, Goettingen, Greifswald, Halle Saale, Hamburg, Hanover, Heidelberg, Herdecke, Homburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Krefeld, Leipzig, Lübeck, Magdeburg, Mainz, Mannheim, Minden, Muenster, München, Munich, Nuremberg, Nürnberg, Oldenburg, Regensburg, Rostock, Sankt Augustin, Schwerin, Stuttgart, Tuebingen, Ulm, Wuerzburg
- Age
- Up to 64 years
- People
- 1,351 worldwide
- Run by
- GPOH gGmbH
See details and how to join2022-501180-40-00 · EU 2022-501180-40-00 - Phase 1Taking peoplePhase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
- Where
- Essen
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07261631 - Phase 3Taking peopleSurgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
- Where
- Dresden, Goettigen, Mannheim
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04031677 - Phase 1Taking peopleLong-term follow-up of patients treated with GD2IL18CART
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 20
- Run by
- Universitaet Muenster
See details and how to join2025-521497-34-00 · EU 2025-521497-34-00 - Phase 1Taking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Essen
- Age
- 18 years and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00 - Phase 1/2Taking peopleFirst-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
- Where
- Essen
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Adcendo ApS
See details and how to joinNCT06797999 · EU 2024-516900-41-00 - Phase 1Taking peopleA phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 48
- Run by
- Universitaet Muenster
See details and how to join2022-501725-21-00 · EU 2022-501725-21-00 - Phase 3Taking peopleA Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- Where
- Bad Saarow, Hanover, Leipzig
- Age
- 18 years and over
- People
- 333 worldwide
- Run by
- Intensity Therapeutics, Inc.
See details and how to joinNCT06263231 · EU 2024-512423-36-00 - Phase 1Taking peopleInternational open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide in pediatric, adolescent, and adult patients with GD2-positive Ewing sarcoma
- Where
- Berlin, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Greifswald, Hamburg, Heidelberg, Leipzig, Mainz
- People
- 18 worldwide
- Run by
- GPOH gGmbH
See details and how to join2024-515245-42-00 · EU 2024-515245-42-00 - Phase 1/2Taking peopleMaster Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
- Where
- Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen
- Age
- 18 years and over
- People
- 96 worldwide
- Run by
- Anocca AB
See details and how to joinNCT07145450 - Phase 1/2Taking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Dresden, Heidelberg
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 1/2Taking peoplePersonalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
- Where
- Berlin, Dresden, Essen, Frankfurt Am Main, Freiburg, Munich, Tuebingen
- Age
- 2 years to 40 years
- People
- 30
- Run by
- University Hospital Tuebingen
See details and how to joinNCT06094101 · EU 2024-511337-35-00 - No phaseTaking peopleNeoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
- Where
- Heidelberg
- Age
- 18 years and over
- People
- 64
- Run by
- University Hospital Heidelberg
See details and how to joinNCT04219202 - Phase 1Taking peopleFIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
- Where
- Tübingen
- Age
- 18 years and over
- People
- 89
- Run by
- German Cancer Research Center
See details and how to joinNCT05999396 - Phase 3Taking peopletTF-NGR Randomized Study - STS
- Where
- Augsburg, Bad Saarow, Berlin, Dresden, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Jena, Leipzig, Mainz, Muenster, Munich
- Age
- 18 years to 75 years
- People
- 126
- Run by
- Universität Münster
See details and how to joinNCT05597917 · EU 2024-516392-33-00 - No phaseTaking peopleSAVE Studie- SArcoma Surgery With Vacuum Enhanced Wound Treatment Randomised Study to Evaluate the Wound Management in Sarcoma Surgery
- Where
- Hamburg
- Age
- 18 years and over
- People
- 100
- Run by
- Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT06889532 - Phase 2Taking peoplePasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
- Where
- Essen, Heidelberg, Stuttgart
- Age
- 13 years to 50 years
- People
- 28
- Run by
- University Hospital Heidelberg
See details and how to joinNCT06456359 · EU 2024-511935-86-00 - No phaseTaking peopleStereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Where
- Hamburg
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767 - Phase 1/2Taking peopleFaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
- Where
- Aachen, Augsburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dortmund, Dresden, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Goettingen, Greifswald, Halle (Saale), Hamburg, Hanover, Heidelberg, Homburg, Jena, Kassel, Kiel, Köln, Leipzig, Luebeck, Magdeburg, Mainz, Mannheim, Muenster, München, Munich, Regensburg, Rostock, Stuttgart, Tübingen, Tuebingen, Ulm, Wuerzburg
- People
- 1,672 worldwide
- Run by
- University of Birmingham
See details and how to joinNCT04625907 · EU 2024-510579-40-00